Table 2.
Main characteristics of patients with OLDs⁎
| Patients with OLDs from whom liver specimens were obtained | |||||||
|---|---|---|---|---|---|---|---|
| Patients (female/male) | Age (years) | ALP (IU/L) | GGT (IU/L) | ALT (IU/L) | AST (IU/L) | Bilirubin (mg/dl) | |
| ALD | 0 / 13 | 56.1 ± 9.4 | 329.3±190.7 | 103.1 ± 99.7 | 41.1 ± 19.0 | 56.2 ± 19.8 | 3.8 ± 1.9 |
| NAFLD | 2 / 2 | 58.9 ± 11.7 | 275.8 ± 92.3 | 199.8 ± 61.2 | 117.3 ± 81.6 | 41.7 ± 14.6 | 0.7 ± 0.4 |
| TxH | 0 / 1 | 70.7 | 1632.0 | 914.0 | 77.0 | 80.0 | 5.4 |
| VHC | 0 / 3 | 59.7 ± 16.6 | 131.0 ± 30.1 | 33.3 ± 21.5 | 44.0 ± 19.3 | 22.7 ± 2.1 | 0.9 ± 0.5 |
| PSC | 0 / 1 | 54.6 | 1598.0 | 309.0 | 52.0 | 48.0 | 5.6 |
| SBC | 1 / 1 | 68.5 ± 4.5 | 574.5±632.9 | 103.0±108.9 | 12.0 ± 5.7 | 16.5 ± 3.5 | 1.0 ± 0.4 |
| Patients with OLDs from whom PBMC specimens were obtained | |||||||
| Patients (female/male) | Age (years) | ALP (IU/L) | GGT (IU/L) | ALT (IU/L) | AST (IU/L) | Bilirubin (mg/dl) | |
| ALD | 1 / 10 | 57.6 ± 5.9 | 202.6 ± 59.2 | 31.4 ± 14.7 | 16.2 ± 10.4 | 28.5 ± 9.7 | 5.6 ± 4.3 |
| NAFLD | 0 / 1 | 46.0 | 109.0 | 38.0 | 70.0 | 28.0 | 1.4 |
| TxH | 1 / 0 | 45.0 | 1321.0 | 815.0 | 71.0 | 76.0 | 5.1 |
| VHC | 5 / 5 | 57.5 ± 13.8 | 124.9 ± 33.6 | 24.7 ± 18.0 | 61.7 ± 45.8 | 44.1 ± 34.0 | 0.6 ± 0.3 |
| PSC | 0 / 1 | 55.0 | 184.0 | 39.0 | 10.0 | 24.0 | 4.5 |
| SBC | 0 / 1 | 59.0 | 133.5 | 27.0 | 9.5 | 22.5 | 4.1 |
ALD, alcohol-related liver disease; ALP, serum alkaline phosphatase; ALT, serum alanine aminotransferase; AST, serum aspartate aminotransferase; GGT, serum gamma glutamyltransferase; NAFLD, non-alcoholic fatty liver disease; OLDs, other liver diseases; PBMCs, peripheral blood mononuclear cells; PSC, primary sclerosing cholangitis; SBC, secondary biliary cirrhosis; TxH, toxic hepatitis; VHC, viral hepatitis C.
*
The most relevant characteristics (mean ± SD) of patients with OLDs from whom either liver samples or PBMCs were obtained, are indicated. Each OLD population was classified according to the ethology.